These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 24940957)

  • 1. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO).
    Treuer T; Anders M; Bitter I; Dobre G; Pecenak J; Dyachkova Y; Harrison G; O'Mahoney J
    Int J Psychiatry Clin Pract; 2006; 10(2):78-90. PubMed ID: 24940957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].
    Brunner E; Gargoloff P; Caro O; González C; Landa E; González CH; Barahona A; Soria D; Tamayo J; Rovner J; Adrianzen C; Silva H; Hodge A; O'Halloran R; Assunção SS;
    Actas Esp Psiquiatr; 2006; 34(1):16-27. PubMed ID: 16525901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Lee P; Eung Kim C; Yoon Kim C; Lin WW; Habil H; Dyachkova Y; Mcbride M; Dossenbach M
    Int J Psychiatry Clin Pract; 2008; 12(3):215-27. PubMed ID: 24931661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intercontinental schizophrenia outpatient health outcomes (ic-soho) study: baseline clinical and functional characteristics and antipsychotic use patterns in the central and eastern europe (cee) region.
    Korb FA; Trzebiatowska I; Janikova E; Winkler-Skaza V; Ilies D; Peciukaitiene D; Anders M; Simon L; Smulevich AB; Dossenbach M
    Psychiatr Danub; 2003 Dec; 15(3-4):163-74. PubMed ID: 19114924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
    Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
    Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Novick D; Haro JM; Perrin E; Suarez D; Texeira JM
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):542-50. PubMed ID: 19500949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
    Rovner J; Assunção S; Gargoloff P; Ibarra HS; Gasca JA; Fournais EL; Adan P; Andrades NJ; Dyachkova Y
    Vertex; 2005; 16(63):332-41. PubMed ID: 16220148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Bitter I; Treuer T; Dyachkova Y; Martenyi F; McBride M; Ungvari GS
    Eur Neuropsychopharmacol; 2008 Mar; 18(3):170-80. PubMed ID: 17884390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the findings from the European SOHO study.
    Suarez D; Haro JM
    Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
    Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D;
    Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia Outpatient Health Outcomes study: twelve-month findings.
    Novick D; Ascher-Svanum H; Haro JM; Bertsch J; Takahashi M
    Pragmat Obs Res; 2012; 3():27-40. PubMed ID: 27774015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study.
    Novick D; Bousono M; Suarez D; Olivares JM; Montejo AL; Haro JM; Edgell ET; Ratcliffe M;
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):972-82. PubMed ID: 16023776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Pragmat Obs Res; 2012; 3():41-49. PubMed ID: 27774016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review.
    Szkultecka-Dębek M; Walczak J; Augustyńska J; Miernik K; Stelmachowski J; Pieniążek I; Obrzut G; Pogroszewska A; Paulić G; Damir M; Antolić S; Tavčar R; Indrikson A; Aadamsoo K; Jankovic S; Pulay AJ; Rimay J; Varga M; Sulkova I; Veržun P
    Clin Pract Epidemiol Ment Health; 2015; 11():158-65. PubMed ID: 26535049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness in Terms of Treatment Discontinuation of Orodispersable Versus. Standard Oral Olanzapine Tablets in Non-Adherent Patients: Results from a 1-Year European Outpatient Observational Study.
    Novick D; Montgomery W; Treuer T; Aguado J; Kraemer S; Haro JM
    Value Health; 2014 Nov; 17(7):A766. PubMed ID: 27202812
    [No Abstract]   [Full Text] [Related]  

  • 19. The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics.
    Leucht S; Rossum IW; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE
    Focus (Am Psychiatr Publ); 2016 Jul; 14(3):378-386. PubMed ID: 31997959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis.
    Peng Z; Jia Q; Mao J; Yi Q
    Neuropsychiatr Dis Treat; 2023; 19():2295-2308. PubMed ID: 37908559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.